Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO

Apnimed Inc., a drug developer in late-stage trials for sleep apnea treatments, filed to raise up to $160 million through a US initial public offering. The company is backed by Shionogi, a Japanese pharmaceutical firm. The offering size and pricing have not yet been finalized.

Next story